$0.52
$1.78
52-Week Range
At a Glance
AI-generated6-K
Zentek Ltd. announced that its wholly-owned subsidiary Triera Biosciences plans to offer contract research organization services for custom aptamer discovery, biosensor enablement, and machine-learning classification, backed by an exclusive 20-year worldwide royalty-bearing license from McMaster University. This targets high-priority infectious disease and oncology detection markets to generate client-funded revenue while retaining IP ownership.$59M
Market Cap
$1M
Revenue
-$11M
Net Income
Employees24
Fundamentals
How The Business Makes Money
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Industry Medical - Instruments & Supplies
Activity
What Changed Recently
Company Profile
CIK0001904501
ISINCA98942X1024
CUSIP98942X102
Phone844 730 9822
Address1205 Amber Drive, Guelph, ON, P7B 6M4, CA
SEC EDGAR